drugset / Trial / NCT02349152

Remifentanil and Glycemic Response in Cardiac Surgery

NCT02349152

Phase 4 Completed 116 enrolled Kathirvel Subramaniam Mylan · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery to supress the hyperglycemic response in perioperative period. Half of the participants will receive continuous intravenous remifentanil during surgery, while the other half will receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl administration is this institution's standard of care.

Timeline

Start
2016-01
Primary completion
2016-12
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fentanyl Other / unclassified 50 ug Intravenous
Comparator Fentanyl Other / unclassified 250 ug Intravenous
Subject Remifentanil Small molecule 0.1 ug/kg Intravenous
Subject Remifentanil Small molecule 0.4 ug/kg Intravenous
Subject Remifentanil Small molecule 0.5 ug/kg Intravenous
Subject Remifentanil Small molecule 1 ug/kg Intravenous